IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

NCT04826159 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes
Diabetic Cardiomyopathies
HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: IMB-1018972

Sponsor

Imbria Pharmaceuticals, Inc.

Collaborators

[object Object]